Context
Apnimed is a biotech preparing to launch a first-to-market oral therapy for OSA. With many diagnosed patients untreated or undertreated by existing options, the company saw an opportunity to activate patients in a new way. The team wanted to build a channel strategy that could support launch, improve access, and create a strong patient experience from awareness through prescription.
Approach
Aytza helped Apnimed map the full range of possible telemedicine and direct-to-patient channel models, then identified and designed the model which was the strongest fit for Apnimed’s launch goals, target patients, medication profile, and commercial needs:
- Defined the different partnership models available across pharma-directed telemedicine, consumer telehealth, virtual sleep clinics, DTP platforms, and adjacent channels
- Clarified how each model works, including the patient experience, commercial structure, ownership of the channel, and operational requirements
- Identified which models best fit Apnimed’s near-term launch priorities and longer-term commercialization strategy
- Mapped and assessed potential partners within the prioritized segments using Apnimed-specific criteria, shortlisting the best fit
- Created a practical implementation plan for partner outreach, diligence, and execution, including detailed RFP questions and metrics
Results
Apnimed came away with a clear view of which partnership models to pursue, which partners to prioritize, and how the commercial pieces could fit together.
The work gave the team a structured path from strategy to execution, helping them advance launch planning, align internally, and prepare for partner conversations.
“We’ve been presenting to leadership and there’s always some random question that comes up, but because we took this systematic approach I’m never stumped. The feedback has been ‘wow, any angle that we could have thought about, we thought about.’”
- Sonnie Kang, VP Commercial Strategy, Apnimed
